Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia

  • Deconstructing the Supermarket: Systematic Ingredient Disaggregation and the Association between Ingredient Usage and Product Health Indicators for 24,229 Australian Foods and Beverages

    Nutrients Date published:

  • Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

    Stroke Date published:

  • Budget impact and cost-effectiveness analyses of the COBRA-BPS multicomponent hypertension management programme in rural communities in Bangladesh, Pakistan, and Sri Lanka

    The Lancet Global Health Date published:

  • Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease

    Circulation Date published:

  • Pseudofolliculitis Barbae in the Military and the Need for Social Awareness

    Military Medicine Date published:

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

    The Lancet Date published:

  • Sodium, Blood Pressure, and the Likely Massive Avoidable Burden of Cardiovascular Disease

    Circulation Date published:

  • Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

    Kidney International Date published:

  • Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial

    Cardiovascular Research Date published:

  • Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

    The Lancet Oncology Date published:

  • Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

    American Heart Journal Date published:

  • Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program

    Endocrinology, Diabetes & Metabolism Date published:

  • The impact of baseline potassium intake on the dose-response relation between sodium reduction and blood pressure change: systematic review and meta-analysis of randomized trials

    Journal of Human Hypertension Date published:

  • An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

    International Journal of Cardiology Date published:

  • Sodium Reduction: How Big Might the Risks and Benefits Be?

    Heart, Lung and Circulation Date published:

  • Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

    Clinical Journal of the American Society of Nephrology Date published: